Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest Articles
Vansteenkiste J et al. – Darbepoetin alfa Q3W and QW raised Hb levels and maintained mean Hb <12g/dL in both baseline-Hb groups. The [≥]10g/dL baseline-Hb group had fewer transfusions and faster anemia correction.
Methods- Data from a phase 3 randomized trial were retrospectively reanalyzed
- CIA patients with non-myeloid malignancies were randomized 1:1 to 500 mcg darbepoetin alfa Q3W or 2.25 mcg/kg darbepoetin alfa QW for 15 w
- This study re-analyzed 351 and 354 patients who initiated ESA therapy at a baseline Hb of <10g/dL or ≥ 10g/dL, respectively
- From week 5 to EOTP, the estimated Kaplan-Meier transfusion incidence (Q3W vs QW) was lower in the [greater than or equal to]10g/dL baseline-Hb group (14% vs 21%) compared with the <10g/dL baseline-Hb group (36% vs 41%)
- By week 5, the ≥ 10g/dL baseline Hb group, but not the <10g/dL baseline-Hb group, achieved a mean Hb ≥ 11g/dL
- The Kaplan Meier estimate of percentage of patients (Q3W vs QW) who achieved Hb ≥ 11g/dL from week 1 to EOTP was 90% vs 85% in the ≥ 10g/dL baseline-Hb group and 54% vs 57% in the <10g/dL baseline-Hb group
- Both baseline-Hb groups maintained mean Hb levels <12g/dL and had similar safety profiles, though more patients in the ≥ 10g/dL baseline-Hb group reached the threshold Hb of ≥ 13 g/dL
Related Articles
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09
Relevance Score: 66%
Anemia Drug May Raise Stroke Risk in Kidney Patients
MedLinePlus, 11/03/09
Relevance Score: 64%
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Shire, 11/30/09
Relevance Score: 43%
Effect of Epoetin Alfa on Survival and Cancer Treatment-Related Anemia and Fatigue in Patients Receiving Radical Radiotherapy With Curative Intent for Head and Neck Cancer
Journal of Clinical Oncology, 11/09/09
Relevance Score: 43%
Human genome sciences submits biologics license application to fda for zalbin
Human Genome Sciences, 11/30/09
Relevance Score: 42%
Today in Anemia/Polycythemia...keeping you current
Receive free subspecialty "5-minute updates" via email
Reference percentiles of hematological and biochemical iron values of blood donors in Port Harcourt, Nigeria
Hematology, 12/02/09
Diabetes mellitus is associated with high early-mortality and poor prognosis in patients with autoimmune hemolytic anemia
Hematology, 12/02/09
The expanding spectrum of thalassemia intermedia
Hematology, 12/02/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
Breast Cancer Research and Treatment, 12/02/09
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action
Breast Cancer Research and Treatment, 12/02/09
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09
Sponsor
Article Search
Sponsor
Sponsor